US 12,016,969 B2
Injectable in vivo crosslinking materials for use as soft tissue fillers
Joseph T. Delaney, Jr., Minneapolis, MN (US); Mark W. Boden, Harrisville, RI (US); John Murphy, Cork (IE); Viktoria Molnar, Dungarvan (IE); Tatyana Dyndikova, Minneapolis, MN (US); Allison Zipp, Saint Michael, MN (US); and Kolbein K Kolste, Boxboro, MA (US)
Assigned to Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed by Boston Scientific Scimed, Inc., Maple Grove, MN (US)
Filed on Feb. 2, 2021, as Appl. No. 17/165,485.
Claims priority of provisional application 62/969,863, filed on Feb. 4, 2020.
Prior Publication US 2021/0236690 A1, Aug. 5, 2021
Int. Cl. A61L 27/16 (2006.01); A61L 27/18 (2006.01); A61L 27/38 (2006.01); A61L 27/50 (2006.01)
CPC A61L 27/16 (2013.01) [A61L 27/18 (2013.01); A61L 27/3839 (2013.01); A61L 27/50 (2013.01)] 18 Claims
OG exemplary drawing
 
1. An injectable in vivo crosslinking material for use as soft tissue filler comprising (a) a reactive multi-arm polymer that comprises a plurality of hydrophilic polymeric arms, the hydrophilic polymer arms comprising poly(2-methyl-2-oxazoline) arms, at least a portion of the hydrophilic polymeric arms comprising one or more reactive end groups and (b) a multifunctional compound that comprises functional groups that are reactive with the reactive end groups of the reactive multi-arm polymer.